NASDAQ$PGEN
Precigen Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter and first half 2022 financial results.
Precigen is focusing on maximizing the value of their highest priority assets and prioritizing capital allocation to reach critical inflection points in clinical trials. The sale of Trans Ova Genetics is expected to close in Q3 2022, providing $170 million in cash up-front and up to a $10 million earn-out over the next two years.
- Expedited prioritized programs, rapidly progressing from Phase 1 dose escalations to 1b expansions and have already initiated Phase 2 studies for several programs.
- Actively pursuing rapid regulatory strategies for licensure to bring potential investigational therapies to patients as quickly as possible.
- Expect additional data this year and early next for prioritized programs, particularly excited for the Phase 1 data presentation for the PRGN-2012 AdenoVerse study in Q4 2022.
- The transaction to sell Trans Ova Genetics, which is expected to close in Q3 2022, will provide Precigen with $170 million in cash up-front and up to a $10 million earn-out over the next two years.
Headline financials
Revenue & EPS history
Precigen · Revenue · Quarterly
$2.91M
Revenue by segment
Precigen · $18.4M total across 3 segments · Q4 2020
- Service revenue$14.3M+18.1%77.7%
- Product revenue$3.95M-25.4%21.5%
- Collab & licensing$148K-44.6%0.8%
Forward guidance
Cash on hand and cost reduction initiatives give enough runway to advance clinical priorities into Q4 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
50%
26 / 52 earnings
Positive
+31.0%
Q2 2023
Best reaction
-38.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +1.7% | -0.2% | — | |
| Q3 2025 | +25.6% | +9.3% | -4.4% | |
| Q2 2025 | +6.1% | +63.9% | +110.6% | |
| Q1 2025 | -2.8% | -5.7% | +0.7% | |
| Q4 2024 | +0.6% | -4.5% | -22.3% | |
| Q3 2024 | -10.4% | -13.0% | -26.1% | |
| Q1 2024 | +6.7% | +2.2% | +25.9% | |
| Q4 2023 | +3.6% | +0.7% | -5.0% | |
| Q3 2023 | -13.5% | -19.8% | -6.3% | |
| Q2 2023 | +31.0% | +43.1% | +39.7% | |
| Q1 2023 | -9.5% | -4.0% | -6.3% | |
| Q4 2022 | +16.4% | -6.0% | -15.5% | |
| Q3 2022 | +11.2% | +18.1% | -2.5% | |
| Q2 2022 | +11.6% | +14.5% | +11.1% | |
| Q1 2022 | +3.2% | +8.0% | +23.2% | |
| Q4 2021 | -1.3% | -10.2% | -6.2% | |
| Q3 2021 | -7.1% | -11.8% | -33.3% | |
| Q2 2021 | +8.6% | +10.4% | +10.6% | |
| Q1 2021 | -0.2% | +5.7% | +9.5% | |
| Q4 2020 | +1.7% | +0.1% | -18.4% | |
| Q3 2020 | +22.2% | +20.4% | +69.7% | |
| Q2 2020 | -5.7% | -8.8% | -1.0% | |
| Q1 2020 | -5.9% | -4.2% | -4.7% | |
| Q4 2019 | -14.5% | -19.0% | -27.4% | |
| Q3 2019 | -1.1% | +2.0% | +6.3% | |
| Q2 2019 | -7.2% | -10.3% | -23.4% | |
| Q1 2019 | -1.1% | +0.7% | +22.2% | |
| Q4 2018 | -38.9% | -39.4% | -36.5% | |
| Q3 2018 | -19.3% | -24.4% | -32.1% | |
| Q2 2018 | -5.7% | -4.6% | -2.9% | |
| Q1 2018 | -19.5% | -13.0% | -9.3% | |
| Q4 2017 | +23.6% | +20.9% | +17.7% | |
| Q3 2017 | -25.3% | -19.7% | -15.9% | |
| Q2 2017 | -5.2% | -4.0% | -15.0% | |
| Q1 2017 | +21.5% | +32.0% | +15.0% | |
| Q4 2016 | +5.8% | +2.1% | -11.0% | |
| Q3 2016 | +14.1% | +24.0% | +15.7% | |
| Q2 2016 | +3.3% | +4.5% | +0.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +17.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | -2.9% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +5.5% | — | — | |
| Q3 2012 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | -7.8% | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro